ProCE Banner Activity

CE / CME

Opportunities and Challenges in Management of Metastatic Colorectal Cancer

Text Module

Get up to date on the NPs’/PAs’ evolving role in caring for patients with metastatic colorectal cancer with this interactive text module sharing insights from Robert Lentz, MD.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: May 02, 2023

Expiration: May 01, 2024

No longer available for credit.

Share

Faculty

Robert Lentz

Robert Lentz, MD

Assistant Professor of Medicine
Department of Medicine
Division of Medical Oncology
University of Colorado School of Medicine and Cancer Center
Aurora, Colorado

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp and Taiho Oncology Inc.

Merck Sharp & Dohme Corp.

Taiho Oncology Inc

Target Audience

NPs, PAs, and nurses who specialize in oncology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patient- and disease-related factors that can affect selection of therapy for mCRC

  • Formulate strategies for use of novel therapies in mCRC

  • Apply recommendations to manage AEs of novel therapies for mCRC

Disclosure

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity

Primary Author

Robert Lentz, MD

Assistant Professor of Medicine
Department of Medicine
Division of Medical Oncology
University of Colorado School of Medicine and Cancer Center
Aurora, Colorado

Robert Lentz, MDresearcher: ALX Oncology, Lilly, Merck.



The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 02, 2023, through May 01, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

 You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours, including 1.00 hours of pharmacology credit. 

AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until May 01, 2024. PAs should only claim credit commensurate with the extent of their participation. 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.